酒精性肝炎市場 - 全球和區域 - 分析和預測（2025-2035年）

全球酒精性肝炎市場的主要驅動力是全球酒精消費量的增加、酒精相關肝病盛行率的增加以及人們對肝臟健康的認知的提高。

酒精性肝炎是一種嚴重的酒精性肝損傷，其發病率和死亡率極高，仍然是一個嚴重的健康問題。診斷方法和早期篩檢計畫的進展提高了疾病的識別和管理等級，推動了對更有效治療方法的需求。目前的治療策略主要包括皮質類固醇和營養支持，但研究正轉向開發新型抗發炎藥物、生物製藥和分子標靶療法。腫瘤壞死因子抑制劑和幹細胞療法等新方法也研究中，為改善患者預後提供了新的價值。

然而，市面上缺乏針對特異性疾病的治療方法，這帶來了許多挑戰，包括治療方案有限和臨床療效參差不齊。此外，酒精使用疾患的社會污名化和漏診也可能導致患者無法獲得治療。同時，開發中國家的醫療基礎設施不斷改善，公共衛生措施也應對酒精相關危害，擴大了治療的可近性，帶來了成長機會。此外，製藥公司積極投資研發，以滿足尚未滿足的需求並改善治療效果，這有望推動酒精性肝炎市場的創新和長期成長。

影響

藥物開發、診斷和病患監測解決方案的技術進步推動酒精性肝炎市場的發展。新的治療方法和非侵入性診斷工具改善早期發現、治療效果和長期疾病管理，尤其是在重症病例中。

需求 - 促進因素與限制因素

全球酒精性肝炎市場需求促進因素：

• 全球酒精性肝病的盛行率不斷上升，尤其是在酒精消費量高的地區
• 提高大眾對肝臟健康的認知和擴大篩檢舉措將鼓勵更早的醫療干預
• 高復發率和再入院率需要長期疾病管理，對藥物治療和支持治療產生持續的需求

全球酒精性肝炎市場的限制

• 新興市場中肝病專家和先進治療方案的可及性有限
• 與酒精相關疾病相關的恥辱感導致診斷不足和治療依從性差，阻礙了市場成長。

本報告全面洞察酒精性肝炎的當前趨勢，幫助企業識別藥物和技術開發機會。企業可以利用這些洞察，根據酒精性肝炎患者的需求設計個人治療方法、藥物和平台，改善療效並提高市場滲透率。

競爭格局：詳細的競爭格局分析可以幫助企業與Aldeyra Therapeutics和Intercept Pharmaceuticals等主要企業進行市場定位比較。了解競爭對手的優勢和劣勢，可以幫助企業在全球酒精性肝炎市場中更有效地定位。

主要市場參與企業和競爭對手的摘要

本報告中的公司簡介是根據其在全球酒精性肝炎市場中的存在、產品系列和競爭定位而選擇的。

全球酒精性肝炎市場的主要企業是：

• Aldeyra Therapeutics
• Intercept Pharmaceuticals, Inc.
• DURECT Corporation

本報告研究了全球酒精性肝炎市場，提供了市場概述以及區域趨勢和參與市場的公司概況。

目錄

執行摘要

第1章 全球酒精性肝炎市場：產業展望

• 市場概覽
• 市場趨勢
• 酒精性肝炎流行病學分析
• 臨床試驗
• 監管狀況/合規性
• 市場動態
  • 影響分析
  • 市場促進因素
  • 市場限制
  • 市場機會

第2章 全球酒精性肝炎市場（依地區），百萬美元，2023-2035年

• 北美洲
• 歐洲
• 亞太地區

第3章 全球酒精性肝炎市場 - 競爭基準化分析與公司簡介

• 競爭格局
  • 關鍵策略和發展
• 公司簡介
  • Aldeyra Therapeutics, Inc.
  • Alfasigma Group（Intercept Pharmaceuticals, Inc.）
  • DURECT Corporation

第4章 調查方法

Global Alcoholic Hepatitis Market: Industry Overview

The global alcoholic hepatitis market is primarily driven by the increasing prevalence of global alcohol consumption, rising alcohol-related liver diseases, and increased public awareness of liver health. Alcoholic hepatitis, a severe form of alcohol-induced liver injury, remains a significant health concern with high morbidity and mortality rates. Advancements in diagnostic methods and early screening programs have improved the identification and management of this condition, prompting a growing demand for more effective therapies. Current treatment strategies primarily include corticosteroids and nutritional support; however, research is advancing toward the development of novel anti-inflammatory agents, biologics, and targeted molecular therapies. Emerging approaches such as TNF inhibitors and stem cell therapies are also being explored, offering new virtues to improve patient outcomes.

However, the market does face challenges such as the absence of disease-specific treatments, which restricts therapeutic options and leads to variability in clinical outcomes. Moreover, social stigma and underdiagnosis of alcohol use disorders can delay patient access to care. On the other hand, growth opportunities are emerging from expanding access to treatment in developing countries, where healthcare infrastructure is improving and public health initiatives are addressing alcohol-related harm. Further, pharmaceutical companies are actively investing in research and development to address unmet needs and improve therapeutic outcomes, which is expected to drive innovation and long-term growth in the alcoholic hepatitis market landscape.

Impact

Technological advancements in drug development, diagnostics, and patient monitoring solutions are driving progress in the alcoholic hepatitis market. Emerging therapies and non-invasive diagnostic tools are improving early detection, treatment outcomes, and long-term disease management, especially in severe cases.

Demand - Drivers and Limitations

Demand Drivers for the Global Alcoholic Hepatitis Market:

• Increasing global incidence of alcohol-related liver diseases, particularly in regions with high alcohol consumption
• Heightened public awareness of liver health and expanded screening initiatives promote earlier medical engagement
• High relapse and readmission rates necessitate long-term disease management, creating sustained demand for pharmacological and supportive care

Limitations for the Global Alcoholic Hepatitis Market:

• Limited access to liver specialists and advanced treatment options in emerging markets
• Stigma associated with alcohol-related diseases can lead to underdiagnosis and poor treatment adherence, thereby hindering the market growth.

How can this report add value to an organization?

Product/Innovation: This report provides comprehensive insights into the current trends in alcoholic hepatitis, helping companies identify opportunities for drug and technology development. Organizations can leverage these insights to design therapies, medications, and platforms tailored to the needs of patients suffering from alcoholic hepatitis, improving outcomes and enhancing market penetration.

Competitive: A detailed competitive landscape analysis helps organizations benchmark their market standing against key players such as Aldeyra Therapeutics and Intercept Pharmaceuticals. By understanding the strengths and weaknesses of competitors, companies can position themselves more effectively in the global alcoholic hepatitis market.

Key Market Players and Competition Synopsis

The companies profiled in this report have been selected based on their market presence, product portfolio, and competitive positioning in the global alcoholic hepatitis market.

Leading players in the global alcoholic hepatitis market include:

• Aldeyra Therapeutics
• Intercept Pharmaceuticals, Inc.
• DURECT Corporation

Table of Contents

Executive Summary

Scope of Study

1. Global Alcoholic Hepatitis Market: Industry Outlook

• 1.1 Market Overview
• 1.2 Market Trends
• 1.3 Epidemiological Analysis of Alcoholic Hepatitis
• 1.4 Clinical Trials
• 1.5 Regulatory Landscape / Compliance
• 1.6 Market Dynamics
  • 1.6.1 Impact Analysis
  • 1.6.2 Market Drivers
  • 1.6.3 Market Restraints
  • 1.6.4 Market Opportunities

2. Global Alcoholic Hepatitis Market (By Region), $Million, 2023-2035

• 2.1 North America
  • 2.1.1 Market Dynamics
  • 2.1.2 Market Size and Forecast
    • 2.1.2.1 North America Alcoholic Hepatitis Market, by Country
      • 2.1.2.1.1 U.S.
• 2.2 Europe
  • 2.2.1 Market Dynamics
  • 2.2.2 Market Size and Forecast
    • 2.2.2.1 Europe Alcoholic Hepatitis Market, by Country
      • 2.2.2.1.1 U.K.
      • 2.2.2.1.2 Germany
      • 2.2.2.1.3 France
      • 2.2.2.1.4 Italy
      • 2.2.2.1.5 Spain
• 2.3 Asia-Pacific
  • 2.3.1 Market Dynamics
  • 2.3.2 Market Size and Forecast
    • 2.3.2.1 Asia-Pacific Alcoholic Hepatitis Market, by Country
      • 2.3.2.1.1 Japan

3. Global Alcoholic Hepatitis Market - Competitive Benchmarking and Company Profiles

• 3.1 Competitive Landscape
  • 3.1.1 Key Strategies and Developments
    • 3.1.1.1 Funding Activities
    • 3.1.1.2 Mergers and Acquisitions
    • 3.1.1.3 Regulatory Approvals
    • 3.1.1.4 Partnerships, Collaborations and Business Expansions
• 3.2 Company Profiles
  • 3.2.1 Aldeyra Therapeutics, Inc.
    • 3.2.1.1 Company Overview
    • 3.2.1.2 Product Portfolio
    • 3.2.1.3 Target Customers/End Users
    • 3.2.1.4 Analyst View
  • 3.2.2 Alfasigma Group (Intercept Pharmaceuticals, Inc.)
    • 3.2.2.1 Company Overview
    • 3.2.2.2 Product Portfolio
    • 3.2.2.3 Target Customers/End Users
    • 3.2.2.4 Analyst View
  • 3.2.3 DURECT Corporation
    • 3.2.3.1 Company Overview
    • 3.2.3.2 Product Portfolio
    • 3.2.3.3 Target Customers/End Users
    • 3.2.3.4 Analyst View

4. Research Methodology

List of Figures

• Figure: Global Alcoholic Hepatitis Market, Market Overview
• Figure: Global Alcoholic Hepatitis Market, Epidemiological Analysis
• Figure: Global Alcoholic Hepatitis Market Key Trends, Impact Analysis, 2023-2035
• Figure: Global Alcoholic Hepatitis Market, Competitive Landscape, January 2022-April 2025

List of Tables

• Table: Global Alcoholic Hepatitis Market, Regulatory Scenario
• Table: Global Alcoholic Hepatitis Market Dynamics, Impact Analysis